Advances in ADC Therapy for Ovarian Cancer
Panelists discuss how the rapidly expanding ovarian cancer ADC pipeline offers promising therapeutic options with diverse payloads targeting folate receptor alpha and HER2, providing sequencing opportunities and personalized treatment approaches despite varying toxicity profiles.
EP: 1.Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
EP: 2.The Role of Molecular Testing in Ovarian Cancer Care
EP: 3.From Challenges to Solutions: Ensuring Timely and Effective Molecular Testing in Ovarian Cancer
EP: 4.Mirvetuximab Soravtansine in Ovarian Cancer: Clinical Perspectives and Key Insights from MIRASOL
EP: 5.Advances in ADC Therapy for Ovarian Cancer
EP: 6.Making the Most of ADCs: Balancing Benefits and Managing Concerns in Ovarian Cancer
ADC Pipeline and Emerging Therapeutic Options
The development pipeline for ovarian cancer ADCs is rapidly expanding. Several agents are in clinical trials targeting folate receptor alpha and HER2, with varying payloads including topoisomerase inhibitors and microtubule disruptors. One agent, designed to treat patients with low folate receptor alpha expression, was discontinued despite promising activity.
Excitement surrounds a new ADC that allows for any level of folate receptor expression and shows efficacy with lower toxicity, primarily bone marrow suppression. A key advantage of these agents is payload diversity, offering sequencing opportunities when patients develop resistance or toxicity to one type.
Other promising ADCs target HER2, and basket studies have shown high response rates in HER2-expressing tumors. Toxicity management varies by drug, with some causing ocular issues and others pneumonitis. The evolving ADC landscape underscores the need for broad testing, multiple treatment options, and alignment with patient preferences for personalized care.
